Sugi Predict

Sugi Predict / Compounds / SCHEMBL505984

SCHEMBL505984

SCHEMBL505984

Brc1cccc2occc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 6/20 0.45
▸ MAOA P21397 5/20 0.45
▸ FTO Q9C0B1 1/20 0.45
▸ KCNA3 P22001 1/20 0.40
▸ FADS1 O60427 1/20 0.37
▸ SLC6A2 P23975 1/20 0.36
▸ SLC6A4 P31645 1/20 0.36
▸ SLC6A3 Q01959 1/20 0.36
▸ EED O75530 1/20 0.36
▸ AHR P35869 1/20 0.35
▸ NFKB1 P19838 1/20 0.34
▸ NOS1 P29475 1/20 0.33
▸ AXL P30530 1/20 0.33
▸ HTR2A P28223 1/20 0.32
▸ HTR2C P28335 1/20 0.32
▸ HTR2B P41595 1/20 0.32
▸ BACE1 P56817 1/20 0.32
▸ PARP1 P09874 1/20 0.32
▸ MTNR1A P48039 1/20 0.32
▸ MTNR1B P49286 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL9581639 0.98 MAOB (0.43) MAOBMAOAFTOKCNA3FADS1
SCHEMBL8799961 0.88 MAOB (0.46) MAOBMAOAFTOKCNA3FADS1
SCHEMBL30231603 0.76 MTNR1A (0.46) MAOBMAOAFTOKCNA3NFKB1
SCHEMBL13947728 0.73 MAOA (0.46) MAOBMAOAFTOKCNA3FADS1
SCHEMBL27842814 0.73 MAOA (0.42) MAOBMAOAFTOKCNA3FADS1
SCHEMBL275377 0.71 MAOA (0.50) MAOBMAOAFTOKCNA3FADS1
SCHEMBL275378 0.71 MAOA (0.45) MAOBMAOAFTOKCNA3FADS1
SCHEMBL827237 0.71 MAOA (0.50) MAOBMAOAFTOKCNA3FADS1
SCHEMBL788355 0.71 MAOA (0.45) MAOBMAOAFTOKCNA3FADS1
SCHEMBL824913 0.71 CYP3A4 (0.48) MAOBMAOAFTOKCNA3FADS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121584000-A Composite electrolyte, positive electrode plate and all-solid-state battery 绿能起源科技(江苏)有限公司 2026-02-27 — — CN claimed
CN-117645631-A Organic compound, hole transport layer material, and solar cell 隆基绿能科技股份有限公司 2024-03-05 — — CN claimed
CN-117327048-A Polyarylthio light-control material and preparation method thereof 宁波工程学院 2024-01-02 — — CN claimed
CN-113122061-A Quantum dot ink and preparation method of quantum dot film TCL集团股份有限公司 2021-07-16 — — CN claimed
EP-4729516-A1 SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu NHWA Pharmaceutical Co., Ltd (CN) 2026-04-22 — — EP disclosed
CN-121584000-A Composite electrolyte, positive electrode plate and all-solid-state battery 绿能起源科技(江苏)有限公司 2026-02-27 — — CN disclosed
EP-4624473-A1 PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) 2025-10-01 — — EP disclosed
US-12421228-B2 Naphthyridine derivatives as PRC2 inhibitors Mirati Therapeutics, Inc. (US) 2025-09-23 — — US disclosed
US-20250289789-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2025-09-18 — — US disclosed
US-20250282787-A1 SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS Mirati Therapeutics, Inc. 2025-09-11 — — US disclosed
US-12371435-B2 Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors Mirati Therapeutics, Inc. (US) 2025-07-29 — — US disclosed
US-20250221979-A1 NOVEL HETEROCYCLIC COMPOUND SHOUYAO HOLDINGS BEIJING CO LTD (CN) 2025-07-10 — — US disclosed
EP-0355827-B1 Hydantoin derivatives MOCHIDA PHARM CO LTD (JP) 1997-01-02 — — EP disclosed
US-RE35279-E ALDOSE REDUCTASE INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1996-06-18 — — US disclosed
EP-0560554-A2 Antitumor compositions and methods of treatment ELI LILLY AND COMPANY (US) 1993-09-15 — — EP disclosed
US-5202339-A Hypoglycemic, hypolipedemic agents MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1993-04-13 — — US disclosed
US-5169860-A Benzofuran or benzothiophene arylsulfonylureas ELI LILLY AND COMPANY (US) 1992-12-08 — — US disclosed
US-5004751-A Antidiabetic agents; aldoe reductase inhibitors MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1991-04-02 — — US disclosed
WO-1990002126-A1 HYDANTOIN DERIVATIVES MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1990-03-08 — — WO disclosed
EP-0355827-A2 Hydantoin derivatives MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1990-02-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289789-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF CDK2, CDK20, CDK1 MAOB 1305/4885MAOA 2638/4885FTO 4795/4885
US-12371435-B2 Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors EZH2, BMI1, SUZ12 MAOB 1780/4885MAOA 1952/4885FTO 1812/4885
US-20250221979-A1 NOVEL HETEROCYCLIC COMPOUND MAPT, MNAT1, MAT2A MAOB 593/4885MAOA 353/4885FTO 4056/4885
US-20250282787-A1 SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS EZH2, BMI1, SUZ12 MAOB 4006/4885MAOA 3975/4885FTO 3894/4885
US-12421228-B2 Naphthyridine derivatives as PRC2 inhibitors BMI1, EZH2, SUZ12 MAOB 3533/4885MAOA 3732/4885FTO 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.